Related Experiment Video
Updated: Jul 1, 2026
06:18
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
12.2K
S-Allylmercapto-N-Acetylcysteine (ASSNAC) Attenuates Osteoporosis in Ovariectomized (OVX) Mice
Itay Bleichman1, Sahar Hiram-Bab2, Yankel Gabet2
1Department of Human Molecular Genetics and Biochemistry and Goldschleger Eye Research Institute, School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University, Tel-Aviv 6997801, Israel.
Antioxidants (Basel, Switzerland)
|April 27, 2024
Summary
S-allylmercapto-N-acetylcysteine (ASSNAC) shows promise in treating post-menopausal osteoporosis by reducing bone loss and oxidative stress. Combining ASSNAC with Alendronate enhances bone protection and mitigates Alendronate
Area of Science:
- Biomedical Sciences
- Pharmacology
- Bone Biology
Background:
- Osteoporosis is a significant bone disease, particularly prevalent in post-menopausal women, linked to estrogen deprivation and oxidative stress.
- S-allylmercapto-N-acetylcysteine (ASSNAC), a nuclear factor erythroid 2-related factor 2 (Nrf2) activator, exhibits anti-oxidation properties.
- The study investigates ASSNAC's therapeutic potential in managing post-menopausal osteoporosis.
Purpose of the Study:
- To evaluate the efficacy of ASSNAC, alone and in combination with Alendronate, in preventing bone loss in ovariectomized (OVX) mice.
- To assess the impact of ASSNAC on bone remodeling markers and oxidative stress in OVX mice.
- To determine if ASSNAC can ameliorate Alendronate-induced oxidative stress.
Main Methods:
- Ovariectomized (OVX) female mice were treated with varying doses of ASSNAC and Alendronate.
- Bone morphometry was analyzed using Micro-Computed Tomography (μCT) of the femur and lumbar vertebra.
- Bone remodeling markers (CTX, P1NP) and oxidative stress markers (glutathione, MDA) in bone marrow cells were measured.
Main Results:
- ASSNAC (20 mg/Kg/day) significantly protected against bone loss after 8 weeks post-OVX; higher dose (50 mg/Kg/day) showed protection at 4 weeks.
- Alendronate prevented OVX-induced bone loss, with a synergistic bone-protective effect when combined with ASSNAC.
- ASSNAC and Alendronate combination therapy reduced bone resorption (CTX) and increased bone formation (P1NP); ASSNAC partially attenuated Alendronate-induced oxidative stress.
Conclusions:
- ASSNAC demonstrates therapeutic potential for managing post-menopausal osteoporosis by preserving bone mass and reducing oxidative stress.
- The combination of ASSNAC and Alendronate offers enhanced bone protection compared to Alendronate alone.
- ASSNAC may serve as a complementary therapy to mitigate Alendronate-associated side effects and improve its overall efficacy.
